<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We describe a novel t(16;18)(p13;q21.3) in a male patient with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This unique chromosomal rearrangement has never been described in patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The breakpoint of 16p13 has several hematopoietic <z:hpo ids='HP_0002664'>neoplasm</z:hpo>-related genes such as MHC2TA, a master regulatory gene for HLA-D, and BCMA, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor receptor super-family </plain></SENT>
<SENT sid="3" pm="."><plain>The majority of follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> have a rearrangement of the BCL2 gene, which is a pathogenetic factor in their development </plain></SENT>
<SENT sid="4" pm="."><plain>The diagnostic and prognostic significance of this new translocation is yet to be determined </plain></SENT>
</text></document>